Everything below concerns actin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-27. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
=== Foreign policy === Moore supports Israel's right to defend itself and a two-state solution to the Israeli–Palestinian conflict. In December 2022, he attended the Jewish Community Relations Council of Greater Washington's legislative breakfast, where he said he would be "very aggressive" in promoting trade between Maryland and Israel and promised that one of his first overseas visits would be to Israel. He expressed solidarity with Israel amid the October 7 attacks, and later supported an immediate ceasefire in the Gaza war. In October 2024, Moore criticized a Students for Justice in Palestine event at the University of Maryland, College Park held on the one-year anniversary of the October 7 attack to honor Palestinian civilians killed in the Gaza war, saying that he felt that it was an "inappropriate date for such an event". In May 2026, Moore told Politico that he believed Israeli Prime Minister Benjamin Netanyahu had committed war crimes in the Gaza war, citing his use of food as a negotiating tool. In April 2026, Moore criticized U.S. involvement in the 2026 Iran war, likening it to the war in Afghanistan and fearing it would evolve into "another forever war". He also criticized President Donald Trump for not clearly addressing the American people on what the U.S. is doing in Iran or what success looks like.
Children's is one of four children's hospitals in the state, and its emergency department is one of only two Level I Pediatric Trauma Centers. The Emergency Department at UPMC Children’s Hospital of Pittsburgh treats more than 80,000 patients a year. More than 500,000 infants, children, and adolescents make trips to the hospital every year. Children's ranks in nine of the 10 pediatric subspecialties in the prestigious U.S. News & World Report annual Honor Roll of America's Best Children's Hospitals for 2018–2019. UPMC Children's Hospital of Pittsburgh boasts 1,500,000 square feet (140,000 m2) and has 315 beds, with a 46-bed emergency department and a 36-bed pediatric intensive care unit. A ten-story research center was constructed, with seven out of the ten floors dedicated to pediatric medical research.
Dimethoxytrityl, [bis-(4-methoxyphenyl)phenylmethyl] (DMT) — Removed by weak acid. DMT group is widely used for protection of 5'-hydroxy group in nucleosides, particularly in oligonucleotide synthesis. Methoxytrityl [(4-methoxyphenyl)diphenylmethyl] (MMT) – Removed by acid and hydrogenolysis. Benzyloxymethyl — Comparable stability to MOM, MEM und SEM, but also admits reductive removal: sodium in liquid ammonia, catalytic hydrogenation (palladium hydroxide on activated carbon), or Raney nickel in ethanol Ethoxyethyl ethers (EE) – Cleavage more trivial than simple ethers e.g. 1N hydrochloric acid Methoxyethoxymethyl ether (MEM) — Removed by hydrobromic acid in tetrahydrofuran or zinc bromide in dichloromethane Methoxymethyl ether (MOM) — Removed by 6 M hydrochloric acid in tetrahydrofuran/water Tetrahydropyranyl (THP) — Removed by acetic acid in tetrahydrofuran/water, p‑toluenesulfonic acid in methanol Methylthiomethyl ether — Removed by acid or soft metal oxidants: base-buffered mercuric chloride in wet acetonitrile or silver nitrate in wet tetrahydrofuran Tris(isopropyl)silyloxymethyl (TOM) — Commonly protects 2'-hydroxy function in oligonucleotide synthesis. β‑(Trimethylsilyl)ethoxymethyl — More labile than MEM and MOM to acid hydrolysis: 0.1 M hydrochloric acid in methanol, concentrated hydrofluoric acid in acetonitrile, boron trifluoride etherate in dichloromethane, or tetrabutylammonium fluoride in HMPT (Hexamethyl phosphoric acid triamide) or in tetrahydrofuran Other ethers:
Sources: en.wikipedia.org
=== Reemergence === The use of animal glue, as well as some other types of glues, largely vanished in Europe after the decline of the Western Roman Empire until the 16th to 18th centuries, when wooden furniture started to surge as a major craft. During the Middle Ages, fish glue remained a source for painting and illuminating manuscripts. Since the 16th century, hide glue has been used in the construction of violins. Amerindians used hoof glue primarily as a binder and as a water-resistant coating by boiling it down from leftover animal parts and applying it to exposed surfaces. They occasionally used hide glue as paint to achieve patterns after applying pigments and tanning to hides. Hoof glue would be used for purposes aside from hides, such as as a hair preservative. The Assiniboine preferred longer hair, so they would plaster the strands with a mixture of red earth and hoof glue. It was also used to bind feathers and equipment together.
=== Pharmacokinetics === In healthy individuals, the plasma clearance of methocarbamol ranges between 0.20 and 0.80 L/h/kg. The mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%. The elimination half-life was longer in the elderly, those with kidney problems, and those with liver problems.
British prime minister Keir Starmer said the US could use British bases for "defensive" strikes on Iran and disclosed that Ukrainian and other specialists would aid Gulf efforts to foil Iranian drone strikes. Saudi crown prince Mohammed bin Salman, with US backing, vowed to employ military force against Iranian incursions, calling Iranian strikes "cowardly" due to Saudi airspace being closed to US and Israeli attackers. Trump announced that the US had accepted an Iranian proposal to negotiations. However, Ali Larijani ruled out talks.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.